Grants Search Results

This institution is a member of a research consortium which is being funded by St. Baldrick's: Prognostic significance of gene fusion in low or high risk rhabdomyosarcoma. For a description of this project, see the consortium grant made to the lead institution: Seattle Children's Hospital, Seattle, WA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Prognostic significance of gene fusion in low or high risk rhabdomyosarcoma. For a description of this project, see the consortium grant made to the lead institution: Seattle Children's Hospital, Seattle, WA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Prognostic significance of gene fusion in low or high risk rhabdomyosarcoma. For a description of this project, see the consortium grant made to the lead institution: Seattle Children's Hospital, Seattle, WA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Prognostic significance of gene fusion in low or high risk rhabdomyosarcoma. For a description of this project, see the consortium grant made to the lead institution: Seattle Children's Hospital, Seattle, WA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Comprehensive Approach to Improve Medication Adherence in Pediatric ALL. For a description of this project, see the consortium grant made to the lead institution: the University of Alabama at Birmingham, Birmingham, AL.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Comprehensive Approach to Improve Medication Adherence in Pediatric ALL. For a description of this project, see the consortium grant made to the lead institution: the University of Alabama at Birmingham, Birmingham, AL.

This institution is a member of a research consortium which is being funded by St. Baldrick's: the Multidisciplinary Childhood ALL SPORE Planning Grant. For a description of this project, see the consortium grant made to the lead institution: the New York University Shool of Medicine, New York, NY.

With acute lymphoblastic leukemia (ALL) patients facing a 20% chance of relapse and poor prognosis, as well as substantial short and long term side effects from conventional therapy, novel approaches using targeted therapy based on the intrinsic biology of the ALL blast are urgently needed. The SPORE in Childhood ALL is an ambitious multi-institutional grant that brings together a talented and productive group of basic, translational and clinical investigators who have a strong history of collaborative efforts.  There has never been a SPORE focused on childhood cancer in the history of the National Cancer Institute (NCI), and this grant funds the planning necessary to submit the SPORE for NCI approval.

This institution is a member of a research consortium which is being funded by St. Baldrick's: the Multidisciplinary Childhood ALL SPORE Planning Grant. For a description of this project, see the consortium grant made to the lead institution: the New York University Shool of Medicine, New York, NY.

This institution is a member of a research consortium which is being funded by St. Baldrick's: the Multidisciplinary Childhood ALL SPORE Planning Grant. For a description of this project, see the consortium grant made to the lead institution: the New York University Shool of Medicine, New York, NY.

This institution is a member of a research consortium which is being funded by St. Baldrick's: the Multidisciplinary Childhood ALL SPORE Planning Grant. For a description of this project, see the consortium grant made to the lead institution: the New York University Shool of Medicine, New York, NY.

This institution is a member of a research consortium which is being funded by St. Baldrick's: the Multidisciplinary Childhood ALL SPORE Planning Grant. For a description of this project, see the consortium grant made to the lead institution: the New York University Shool of Medicine, New York, NY.

This institution is a member of a research consortium which is being funded by St. Baldrick's: the Multidisciplinary Childhood ALL SPORE Planning Grant. For a description of this project, see the consortium grant made to the lead institution: the New York University Shool of Medicine, New York, NY.

Non-rhabdomyosarcoma soft tissue sarcoma (NRSTS), the most common class of soft tissue sarcoma, afflicts children and young adults. Unlike children with rhabdomyosarcoma, chemotherapy has failed to improve survival for NRSTS. Of the nearly 50% with intermediate or high-risk NRSTS, only 50% and 15%, respectively, are expected to survive. This consortium is taking advantage of new technology platforms to identify the so-called "actionable mutations" in NRSTS specimens. From this foundation, researchers are able to use molecular genetic data to guide treatment decisions for individual patients with NRSTS. Funds originally administered by the University of Chicago and transferred to the University of Texas Southwestern Medical Center at Dallas.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Molecular targeting in non-rhabdomyosarcoma soft tissue sarcoma Consortium. For a description of this project, see the consortium grant made to the lead institution: the University of Texas Southwestern Medical Center at Dallas, Dallas, TX.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Molecular targeting in non-rhabdomyosarcoma soft tissue sarcoma Consortium. For a description of this project, see the consortium grant made to the lead institution: the University of Texas Southwestern Medical Center at Dallas, Dallas, TX.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Molecular targeting in non-rhabdomyosarcoma soft tissue sarcoma Consortium. For a description of this project, see the consortium grant made to the lead institution: the University of Texas Southwestern Medical Center at Dallas, Dallas, TX.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Molecular targeting in non-rhabdomyosarcoma soft tissue sarcoma Consortium. For a description of this project, see the consortium grant made to the lead institution: the University of Texas Southwestern Medical Center at Dallas, Dallas, TX.

There are currently over 350,000 childhood cancer survivors in the U.S., but treatments often result in persistent late-occurring health problems. One of the most devastating is congestive heart failure (CHF) resulting from treatment with a class of chemotherapy drugs called anthracyclines. It is estimated that 1 in 10 children treated with high-dose anthracyclines will develop CHF, with 1 in 2 dying within five years of diagnosis of CHF. Studies indicate that a low-dose blood pressure medication called carvedilol may help prevent the onset of CHF. This Consortium for Pediatric Intervention Research conducts a clinical trial with collaboration between five COG-member institutions. The project has the potential to not only improve overall cardiac function, but prevent the likelihood of developing CHF in survivors at highest risk. Funds administered by Beckman Research Institute of the City of Hope. Year two of this grant was generously funded by the Rally Foundation.

Lymphoma is the most common cancer in adolescents and young adults (AYA) (15-30 years) and the third most common cancer in children (C) under the age of 15 years (CAYA). This childhood, adolescent and young adult lymphoma cell therapy consortium brings together 8 multidisciplinary academic centers to facilitate targeted cell based translational research in poor-risk and rare lymphomas. This project will likely increase long-term complete remissions, decrease late effects and secondary cancers, reduce health care expenditures and provide a strategy for similar targeted cell based therapy strategies for CAYA patients with poor-risk lymphomas and other similar malignancies. Funds administered by New York Medical College.  

This grant is named for Markit, Ltd. whose 24-hour head-shaving events worldwide have raised over $2.2 million since 2007 to fund life-saving research through the St. Baldrick’s Foundation.